Dr. De la Fuente is the Chief of the Neuro-Oncology Division and Director of the Neuro-Oncology Fellowship Program, Department of Neurology, University of Miami, Neuro-Oncology Clinical Service Leader for the Oncology Service Line at Sylvester Comprehensive Cancer Center and co-chair of the Neuro-Oncology SDG. Dr. De la Fuente is a graduate of the Neuro-Oncology Fellowship program at Memorial Sloan Kettering Cancer Center in New York, where she served as Consultant in the Department of Neurology. Dr. De la Fuente is a member of the Board of Directors of the Society for Neuro-Oncology (SNO) and co-Director of SNO Leadership Program. Dr. De la Fuente has been appointed by the President of the Florida Senate as a Member of the Scientific Advisory Council of the Florida Center for Brain Tumor Research.
Objectives:
1.Demonstrate the value of glioma classification
2.Explain the role of molecular characterization in glioma.
3.Assess the role of novel targeted therapeutics for glioma.
FACULTY DISCLOSURES:
Dr. De la Fuente has indicated that she has relevant financial relationship with commercial interests.
Advisor: Servier Pharmaceuticals, Rigel Pharmaceuticals, AnHeart Therapeutics
Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.
All the relevant financial relationships for these individuals have been mitigated.
TARGET AUDIENCE:
Faculty, Primary Care Physicians, APRNs, PharmD
ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This article was printed from The Miller School of Medicine Medical News
at the following URL: https://events.med.miami.edu/event/novel-targeted-therapeutics-for-glioma/
Copyright © 2024 University of Miami Health System